Sigma Advanced Systems Limited – Investor Presentation Summary

Key Operational Highlights

  • Operational revenue of ₹417.07 crore in Q2 FY27, up 11.43% quarter-on-quarter from ₹374 crore in Q1 FY27.
  • Operational EBITDA of ₹82.28 crore, showing 35.06% growth quarter-on-quarter from ₹61 crore.
  • Sri City aerospace facility commenced production in September 2026; first batch shipped to Sigma UK.
  • Initial stages of Rolls-Royce source-change approval completed.
  • Secured export orders from a North American customer worth ₹1,013 crore for manufacturing and supplying 155mm base bleed artillery shells.
  • In October 2026, secured ₹174 crore order for specialised ancillary subsystems and ₹973 crore order for Base Bleed Units.
  • Secured ₹155 crore in orders for Indrajaal Ranger, an AI-powered, indigenous anti-drone patrol vehicle.

Key drivers of operational performance: New record export wins in 155 mm ammunition, deeper Rolls-Royce partnership through Bromford acquisition, and new operational capacity at Sri City.

Financial Highlights

Revenue: ₹417.07 crore (Q2 FY27)

EBITDA: ₹82.28 crore (Operational EBITDA, Q2 FY27)

PAT: ₹52 crore (Q2 FY27, excludes share of profit/loss from associates)

EPS: Not Specified

Margins: EBITDA Margin 20.6% (Q2 FY27), PAT Margin 12.68% (Q2 FY27)

YoY/QoQ comparison: Revenue increased 11.43% QoQ from ₹374 crore to ₹417 crore; Operational EBITDA increased 35.06% QoQ from ₹61 crore to ₹86 crore; PAT increased from ₹38 crore to ₹52 crore QoQ.

Drivers of financial performance: Higher revenue growth, operational efficiencies, and strategic acquisitions.

Comparison to market estimates: Not Specified

Key Risks: Not explicitly disclosed

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Strong order book visibility with long-term agreements; targeted investments into Capex and working capital requirements for UK facilities.

Capex & Cash Flow Health

Capital Expenditure: Targeted investments made into Capex requirements for UK facilities.

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Focus on capacity expansion, technology upgrades, and automation for operational efficiencies.

Strategic & R&D Initiatives

Investments in Innovation: Acquired Bromford Precision Solutions Limited, UK to cement leadership in global aerospace ecosystem and Rolls-Royce supply chain. Building end-to-end capabilities including precision machining, fabrications, assemblies, treatments, forgings, and composites.

Expected impact on growth: EBITDA improvement by 2-4% by end of FY27; another 4-6% by end of FY28 through transfer of work to low-cost base in India.

Strategic Rationale: Expand value chain presence, strengthen presence in UK and Europe, establish footprint in USA, deepen access across global aerospace OEMs, and activate dual sourcing and margin expansion.

Industry Trends & Business Environment

Macro/Industry Trends: Growing global aerospace and defense market with multi-decade supply chain partnerships.

Impact on Company: Positioned as complete solution supplier with unique global programs and NATO defense programs; strong pipeline of active aerospace and defense bids with contract tenures of up to 10 years.

Management Commentary & Growth Outlook

Strategic Outlook: Focused on continued timely execution to be the partner of choice for growing customer base. Large and growing order book gives visibility and sets clear path to scaled, profitable growth.

FY Guidance: EBITDA improvement targets of 2-4% by end of FY27 and 4-6% by end of FY28 through operational efficiencies.

Market Share Targets: Not Specified

Risks and Opportunities: Not explicitly highlighted

Additional Headings

Board and Management Overview
  • Lt General B. S. Raju (PVSM, UYSM, AVSM, YSM) - Non-Executive Independent Director, 40+ years experience, 44th Vice Chief of the Indian Army Staff
  • Amb Dr. T V Nagendra Prasad - Non-Executive Independent Director, 30+ years experience, recently retired Ambassador to Kazakhstan
  • Kalyan Vijay Sivalenka, CFA - Non-Executive Independent Director, 20+ years experience, Managing Partner at Hyderabad Angels Venture Advisory
  • Jayadev Galla - Non-Executive Independent Director, 35+ years experience, Co-Founder and Chairman of Amara Raja Group
  • U Jeya Shanthi - Non-Executive Independent Director, 36+ years experience, Former Director General (HR), DRDO
  • Kartheek Raju - Executive Vice Chairman, 15+ years experience
  • Sunil Kumar Kalidindi - Group CEO and Managing Director, 20+ years experience
  • Cheemarla Damodar Reddy - Whole Time Director, 35+ years experience
Key Strengths
  • Deep customer relationships with global aerospace OEMs
  • Order book visibility with secure LTAs of ~7 years with take-or-pay provisions and sole source contractual terms for nearly 90% of aerospace orderbook
  • Delegatory approvals from Rolls-Royce for accelerated transfer of work to India
  • Multi-decade supply chain partnership on unique, complex high-value global programs
  • Leading manufacturer and exporter for 155mm Base Bleed artillery ammunition used across European and Global defense OEMs
Geographical Footprint & Operations
  • 5+ decades manufacturing experience across multiple sites in UK and India
  • 23-acre integrated aerospace campus at Sri City with masterplan for 500k sqft of end-to-end manufacturing capabilities
  • Phase 1 facility live at Sri City with vertically integrated state-of-the-art AS9100D certified aerospace and defense manufacturing